WANA PRODUCTS PARTNERS WITH CANNABICS PHARMACEUTICALS TO LAUNCH FIRST-EVER EXTENDED RELEASE CANNABIS CAPSULE


Noelle New Headshot Fmt Headshot

Proprietary delivery system makes medical marijuana more predictable, eliminates dosing concerns

wana logowana logo[Press Release] Boulder, Colo. (June 16, 2015)  – Wana Products today announced the launch of WanaCapsxr, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours. Wana Products has partnered with Cannabics Pharmaceuticals Inc., a U.S. based Drug Development Company with R&D in Israel, that developed the proprietary technology behind the extended release formulation. WanaCapsxr will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCapsxr High CBD Capsules), a 10:1 THC to CBD ratio (WanaCapsxr High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCapsxr THC/CBD Balanced Capsules).

“WanaCapsxr represents the next generation in the evolution of marijuana for the medical community,” said Nancy Whiteman, co-owner of Wana Products. “The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing. Additionally, WanaCapsxr are formulated to be highly bio-available so patients feel the therapeutic impact quickly.”

“The new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness,” Whiteman added. “Instead, with WanaCapsxr, patients experience a long-lasting, stable effect for up to 10 hours without the ups and downs. Overall, it’s just a much better experience for patients.” Each package of WanaCapsxr contains ten 10 mg capsules, allowing for precise dosing based on the patient’s individual needs and tolerance.

Cannabics has tested the capsules with over 100 patients in Israel where medical research on cannabis has been legal since 2008. Test subjects found the capsules to be effective at reducing pain, eliminating nausea, and improving sleep, appetite and mood. On the strength of this preliminary feedback, Cannabics is now undertaking a comprehensive clinical trial in partnership with Rambam Hospital in Haifa.

“Cannabics researchers are making breakthroughs in the medical evolution of cannabis, and WanaCapsxr is on the leading edge of those advancements,” said Dr. Eyal Ballan, Chief Scientist of Cannabics Pharmaceuticals. “Wana’s new XR product will help legal medical marijuana states approach the roll out of medical cannabis in a new and effective way.”

The innovative joint venture between Wana Products and Cannabics Pharmaceuticals, two leading companies in the growing medical marijuana and edibles industries, offers an incredible licensing opportunity of its patented IP technology to emerging markets. On a five-year outlook, the preeminent cannabis data research organization ArcView has found that the legal medical cannabis market is expected to grow to $10.2 billion by 2018.

About Wana Products

Wana Products leads the Colorado’s edibles and medical marijuana industry in quality, consistency and potency. Since 2010, Wana Products has made marijuana infused products including custom hash, vape oil, a full line of edibles, and now WanaCapsxr, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours. Based in Boulder, Colo., Wana Products also provides a variety of equipment, packaging and consulting services to the cannabis industry. For more information, visit www.wanaedibles.com. Become a fan of Wana Products on Facebook. Follow Wana Products on Instagram.

About Cannabics Pharmaceuticals, Inc.

CANNABICS PHARMACEUTICALS, INC. (OTCQB: CNBX) is a US public company with Research & Development conducted in its laboratories in Israel. The company is dedicated to the development of advanced and sophisticated cannabinoid-based treatments and therapies. The Company’s main focus is development and marketing of various novel therapies and biotechnological tools aimed at providing relief from diverse ailments and treating human malignancies. These advanced tools include novel delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds and bioinformatics tools. For more information, visit www.cannabics.com.

Page 1 of 645
Next Page